Gabriel Brooks, MD

Chief medical officer at Solid Biosciences.

Articles by Gabriel Brooks, MD

NeuroVoices: Aravindhan Veerapandiyan, MD; Gabriel Brooks, MD, on Unpacking the SGT-003 Phase 1/2 Biomarker Data in Duchenne

ByIsabella Ciccone, MPH,Aravindhan Veerapandiyan, MD,Gabriel Brooks, MD

March 25th 2026

Experts discussed new biomarker data from a phase 1/2 study, presented at the 2026 MDA Conference, of the gene therapy SGT-003 in boys living with Duchenne muscular dystrophy.

Latest Updated Articles

NeuroVoices: Aravindhan Veerapandiyan, MD; Gabriel Brooks, MD, on Unpacking the SGT-003 Phase 1/2 Biomarker Data in Duchenne
March 25th 2026

Gabriel Brooks, MD

Articles by Gabriel Brooks, MD

NeuroVoices: Aravindhan Veerapandiyan, MD; Gabriel Brooks, MD, on Unpacking the SGT-003 Phase 1/2 Biomarker Data in Duchenne

Latest Updated Articles

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Looking Beyond Gene Therapy for Treating Charcot-Marie-Tooth Disease: Carla Taveggia, PhD

Rethinking Clinical Trial Design and the Immune System in Multiple Sclerosis: Ahmed Obeidat, MD, PhD

AAIC 2026 Preview: David Wolk, MD, on Biomarkers, Disease Heterogeneity, and What's Next in Alzheimer Research

NeurologyLive® Brain Games: July 12, 2026

Large Registry Study Questions Utility of Plasma CGRP as Diagnostic Biomarker for Migraine